Alnylam Pharmaceuticals, Biosaxony and BioInnovation Center Dresden, Cellectricon, and CytRx and Imperial College London

May 28, 2004

Premium

Alnylam Lowers Share Price Range for IPO

Alnylam Pharmaceuticals has lowered the range at which it expects its shares to float in a planned inital public offering to $5 to $8 per share from $10 to $12 per share, according to a company filing with the US Securities and Exchange Commission.

The company still intends on selling 5 million shares of its common stock through the offering, plus an additional 750,000 being offered to the IPO’s underwriters to cover over-allotments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Menu